I would think after the GMU in vitro results, the military conference, and pending clinical trial results, Leo has had contact with various pharmas who are leaning toward partnership for a PH III and beyond, if PH II results are as good as many expect them to be.

There are billions of dollars to be made with a robust therapeutic, and I doubt any C suite officers will be slow to make offers if Brilacidin shows it's therapeutic power.

Right now Leo's hard at work on the annual K filing, but I'll bet some news drops before the end of month, even if it's only the data lock.

Exciting times ahead!